10-K: ImmuCell Corporation Reports Full Year 2023 Results, Navigates Production Challenges While Advancing Re-Tain

ImmuCell Corporation's annual report details a year of production setbacks and strategic investments, while highlighting progress in the development of Re-Tain.

Summary

• ImmuCell Corporation's 2023 annual report reveals a challenging year marked by production contamination events that significantly impacted sales and gross margins.
• Despite these setbacks, the company continued to invest in expanding production capacity for its First Defense product line, aiming for an annual output of approximately $30 million.
• The company experienced three separate contamination events during 2022 and 2023, resulting in a total charge to costs of goods sold of approximately $589,000 in 2022 and $527,000 in 2023.
• ImmuCell is actively working to remediate these issues and believes it has improved processes and controls in place to support large-scale production.
• The company's cumulative sales of First Defense since inception exceeded 33 million doses by the end of 2023.
• ImmuCell is also focused on the development of Re-Tain, a novel treatment for subclinical mastitis, and expects a response from the FDA on its fifth technical section submission by May 2024.
• The company has invested approximately $28.1 million in the development of Re-Tain over the past 24 years.
• Total assets increased to $43.8 million as of December 31, 2023, from $14.6 million as of December 31, 2015, and stockholders' equity increased to $25 million from $10.6 million over the same period.
• The company's share of the calf-level scours preventative market was approximately 48% in 2023, up from 36% in 2019.
• The company estimates the total U.S. market for calf-level scours preventative products to be approximately $25.6 million per year, and the total domestic addressable market (including dam-level products) to be approximately $75.4 million per year.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in product development and market share, the significant production issues and financial losses create a negative sentiment. The company's future outlook is positive, but the near-term challenges are substantial.

Positives

• The company has made significant investments in expanding its production capacity for the First Defense product line, aiming for an annual output of approximately $30 million.
• ImmuCell has achieved a leading market share in the calf-level scours preventative market, with 48% in 2023.
• The company has made substantial progress in the regulatory approval process for Re-Tain, with four out of five technical sections approved by the FDA.
• The company's total assets and stockholders' equity have shown significant growth over the past eight years.
• The company has a strong focus on developing innovative products that address the growing concern about antibiotic use in food-producing animals.

Negatives

• The company experienced significant production contamination events in 2022 and 2023, resulting in substantial charges to costs of goods sold.
• These contamination events led to a slowdown in production output and a significant increase in the order backlog, which reached $9.4 million by the end of 2023.
• The company missed its gross margin goals in 2023 and 2022, with realized gross margins of 22% and 41%, respectively.
• The company's net operating loss increased significantly in 2023 to $5.7 million, compared to $2.3 million in 2022.
• The company is facing supply disruptions and inflationary increases, which are impacting its costs of goods sold.

Risks

• The company faces risks related to the timing and outcome of pending or anticipated regulatory approvals for Re-Tain.
• There are risks associated with the company's ability to maintain adequate cash and liquidity to support the commercialization of Re-Tain.
• The company is exposed to risks related to product contamination events and equipment failures in its production process.
• There are sales risks pertaining to Re-Tain, including potential customer rejection due to milk inhibitor tests or failed cheese tanks.
• The company is reliant on the market acceptance of the First Defense product line to generate product sales and fund its operations.
• The company faces competition from larger and more diversified animal health companies.
• The company is exposed to global risks, including the impact of the war in Ukraine and the Middle East on the world economy and supply chains.
• The company is exposed to risks related to climate change and potential epidemics of bovine diseases.
• The company's stock price can be volatile and may be negatively affected by uncertainties and risks related to product development.

Future Outlook

The company aims to exceed $35 million in annual total product sales within four years after the market launch of Re-Tain. They also plan to increase production output and reduce costs of goods sold per unit. The company is working to expand its product development pipeline of antimicrobials and is interested in acquiring new products and technologies that fit with its sales focus on the dairy and beef industries.

Management Comments

• We believe that the ongoing implementation of our capacity expansion plans and the corrective actions being taken in response to these contamination events should allow us to operate at the higher level of production output going forward without further significant contaminations.
• Our most important customer-focused objectives going forward are to fulfill the large backlog of orders and then again be a reliable supplier of a very effective product to the dairy and beef calf market.
• We believe that societal animal welfare objectives will put more and more pressure on the industry to treat cows with subclinical infections.
• We believe our product fits very well with where the industry is going to be in the coming years.

Industry Context

The report highlights the growing concern about antibiotic use in food-producing animals and the need for alternative solutions, which aligns with broader industry trends. The company's focus on developing a bacteriocin-based treatment for mastitis positions it well to address this concern. The report also notes the volatility in the dairy market and the impact of global supply chain disruptions, which are affecting the entire industry.

Comparison to Industry Standards

• ImmuCell's market share in the calf-level scours preventative market is approximately 48%, indicating a strong position compared to other calf-level competitors like Zoetis' Calf-Guard and Merck's BOVILIS Coronavirus.
• The company's product, Tri-Shield First Defense, competes with dam-level vaccines from companies like Elanco (Scour Bos), Merck (Guardian), and Zoetis (ScourGuard), offering a direct-to-calf approach.
• ImmuCell's Re-Tain is positioned to compete with traditional antibiotic treatments for mastitis from companies like Boehringer Ingelheim, Merck Animal Health, and Zoetis, by offering a treatment without a milk discard requirement.
• The company's market capitalization of approximately $40 million is significantly lower than many other companies in the animal health sector, which often have market capitalizations that greatly exceed this value.

Related Party Transactions

• David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products. His affiliated company purchased $231,405 and $587,677 of products from us during the years ended December 2023 and 2022, respectively, all on terms consistent with those offered to other distributors of similar status.

Stakeholder Impact

• Shareholders are impacted by the company's financial losses and the potential for future capital raises.
• Employees are impacted by the company's production challenges and the need to remediate these issues.
• Customers are impacted by the company's production slowdown and the resulting order backlog.
• Suppliers are impacted by the company's supply chain disruptions and inflationary increases.
• Creditors are impacted by the company's debt service obligations and the need to meet debt covenants.

Next Steps

• The company will continue to work on remediating the production issues and increasing its production output.
• The company will continue to work with the FDA to obtain approval for Re-Tain.
• The company will continue to develop detailed launch plans for Re-Tain, focusing on the readiness of dairy operators to successfully introduce the product to their herds.
• The company will continue to evaluate alternatives for DP supply going forward, which include the resumption of the investment in our own in-house DP services or another contract manufacturing agreement.

Key Dates

Keywords

ImmuCell, First Defense, Re-Tain, mastitis, scours, animal health, bacteriocin, Nisin, FDA approval, production capacity, contamination, dairy, beef, colostrum, antibiotics